The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.
View / Open Files
Publication Date
2022-03-25Journal Title
NPJ genomic medicine
ISSN
2056-7944
Volume
7
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Lago, S. G., & Bahn, S. (2022). The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.. NPJ genomic medicine, 7 (1) https://doi.org/10.1038/s41525-022-00290-4
Description
Funder: Stanley Medical Research Institute
Abstract
There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.
Identifiers
35338153, PMC8956592
External DOI: https://doi.org/10.1038/s41525-022-00290-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/336495
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.